Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small cell lung cancer in a real-world setting (OSI-FACT-EP)-Reference-Cited by-同舟云学术

Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small cell lung cancer in a real-world setting (OSI-FACT-EP)

Published:2023-12 Issue: Volume:186 Page:107426
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Sakata Yoshihiko^ORCID,Saito Go^ORCID,Sakata Shinya,Oya Yuko,Tamiya Motohiro,Suzuki Hidekazu,Shibaki Ryota^ORCID,Okada Asuka^ORCID,Yokoyama Toshihide^ORCID,Matsumoto Hirotaka^ORCID,Otsuki Taiichiro^ORCID,Sato Yuki,Junji Uchida,Tsukita Yoko,Inaba Megumi,Ikeda Hideki,Arai Daisuke^ORCID,Maruyama Hirotaka,Hara Satoshi,Tsumura Shinsuke,Morinaga Jun,Sakagami Takuro^ORCID

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference32 articles.

1. Spanish Lung Cancer Group, Screening for epidermal growth factor receptor mutations in lung cancer;Rosell;N. Engl. J. Med.,2009

2. Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma;Mok;N. Engl. J. Med.,2009

3. North-East Japan Study Group, Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR;Maemondo;N. Engl. J. Med.,2010

4. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 study;Zhou;Lancet Oncol.,2011

5. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Optimization of treatment strategies for elderly patients with advanced non-small cell lung cancer;Frontiers in Oncology;2024-07-16

2. Corrigendum to “Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT-EP)” [Lung Cancer 186 (2023) 107426];Lung Cancer;2024-02

3. Editorial: Mechanisms of drug resistance to targeted therapy in malignancies;Frontiers in Oncology;2024-01-19